Leinonen J, Lövgren T, Vornanen T, Stenman U H
Department I of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Clin Chem. 1993 Oct;39(10):2098-103.
We have developed a procedure for simultaneous immunofluorometric assay (IFMA) of prostate-specific antigen (PSA) and its complex with alpha 1-antichymotrypsin (ACT). A PSA-specific monoclonal antibody, which captures both free PSA and the PSA-ACT complex, was used as solid-phase antibody. Total PSA immunoreactivity was measured with a Eu(3+)-labeled PSA antibody that reacted with both free PSA and PSA-ACT. PSA-ACT was assayed simultaneously with a Sm(3+)-labeled polyclonal ACT antibody as a tracer. As standard we used pooled serum in which most of the PSA occurred as the PSA-ACT complex. The assay range was 0.03-500 micrograms/L for total PSA and 0.16-450 micrograms/L for PSA-ACT. In comparison with the assay for total PSA, assay of the PSA-ACT/PSA ratio improved the clinical specificity for cancer by reducing the number of false-positive results in prostatic hyperplasia.
我们已开发出一种同时免疫荧光测定法(IFMA),用于检测前列腺特异性抗原(PSA)及其与α1 -抗糜蛋白酶(ACT)的复合物。一种能捕获游离PSA和PSA - ACT复合物的PSA特异性单克隆抗体被用作固相抗体。总PSA免疫反应性通过与游离PSA和PSA - ACT均发生反应的铕(Eu³⁺)标记的PSA抗体进行测定。PSA - ACT则同时用钐(Sm³⁺)标记的多克隆ACT抗体作为示踪剂进行检测。我们使用大部分PSA以PSA - ACT复合物形式存在的混合血清作为标准品。总PSA的检测范围为0.03 - 500微克/升,PSA - ACT的检测范围为0.16 - 450微克/升。与总PSA检测相比,PSA - ACT/PSA比值检测通过减少前列腺增生中假阳性结果的数量,提高了癌症的临床特异性。